Bretylol en es it fr

Bretylol Brand names, Bretylol Analogs

Bretylol Brand Names Mixture

  • No information avaliable

Bretylol Chemical_Formula


Bretylol RX_link

Bretylol fda sheet

Bretylol msds (material safety sheet)

Bretylol MSDS

Bretylol Synthesis Reference

No information avaliable

Bretylol Molecular Weight

243.163 g/mol

Bretylol Melting Point

No information avaliable

Bretylol H2O Solubility

Freely soluble

Bretylol State


Bretylol LogP

No information avaliable

Bretylol Dosage Forms

Solution for injection (50mg/mL)

Bretylol Indication

For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.

Bretylol Pharmacology

Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.

Bretylol Absorption

No information avaliable

Bretylol side effects and Toxicity

Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.

Bretylol Patient Information

Bretylol Organisms Affected

Humans and other mammals